Elicio Therapeutics Inc (ELTX) Institutional Ownership & 13F Filings (Q2 2026)

ELTX ranks #5835 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

57 institutions disclose a position in ELTX, but none treat it as a major bet — even Knoll Capital Management, LLC, its most concentrated holder, allocates just 2.2% of its own portfolio to it.

Moody Lynn Lieberson & Walker, LLC has trimmed its ELTX position for two straight quarters, cutting it by $88.7K while still holding $18.2K.

ELTX is up 1.3% today, and institutions have been net buyers of $14.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ELTX reported a net loss of $37.8M over the trailing twelve months.

• Not yet profitable — net loss of $37.8M over the trailing twelve months
• Revenue declined 97.8% year over year
• Net income improved year over year, from -$54.6M to -$37.8M
• Operating cash flow was negative, using $37.0M in cash
• Current ratio of 2.38x — enough short-term assets to cover short-term liabilities
• Liabilities run 14.81x equity — a highly leveraged balance sheet worth noting